Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2016 Aug 19;5(8):e003410.
doi: 10.1161/JAHA.116.003410.

2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population

Affiliations
Comparative Study

2013 ACC/AHA Cholesterol Guideline Versus 2004 NCEP ATP III Guideline in the Prediction of Coronary Artery Calcification Progression in a Korean Population

Yun Kyung Cho et al. J Am Heart Assoc. .

Abstract

Background: Since the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) guidelines, significant controversy has surrounded the applicability of the new cholesterol guidelines and the Pooled Cohort Equations. In this present study, we investigated whether eligibility for statin therapy determined by the 2013 ACC/AHA guidelines on the management of blood cholesterol is better aligned with the progression of coronary artery calcification (CAC) detected by coronary computed tomography angiography (CCTA) than the previously recommended 2004 National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III guidelines.

Methods and results: We enrolled 1246 asymptomatic participants who underwent repeated CAC score measurement during routine health examinations. The CAC score progression was defined as either incident CAC in a population free of CAC at baseline or increase ≥2.5 units between the baseline and final square root of CAC scores participants who had detectable CAC at baseline examination. Application of the ACC/AHA guidelines to the study population increased the proportion of statin-eligible subjects from 20.5% (according to ATP III) to 54.7%. Statin-eligible subjects, as defined by ACC/AHA guidelines, showed a higher odds ratio for CAC score progression than those considered statin eligible according to ATP III guidelines (2.73 [95% CI, 2.07-3.61] vs 2.00 [95% CI, 1.49-2.68]).

Conclusions: Compared with the ATP III guidelines, the new ACC/AHA guidelines result in better discrimination of subjects with cardiovascular risk detected by CAC score progression in an Asian population.

Keywords: Pooled Cohort Equation; atherosclerosis; cardiovascular disease; cholesterol guidelines; coronary artery calcification.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A, Flow diagram of participants who would be eligible for statin therapy according to each set of guidelines and age group. B, Proportion of participants who would be eligible for statin therapy according to each set of guidelines and age group. Proportions were calculated within the total population (N=1289). *“Statin considered” indicates statin candidates who are nondiabetic individuals with 5% to <7.5% 10‐year ASCVD risk among 40 to 75 years of age with LDL‐C 1.8 to 4.9 mmol/L. ACC/AHA indicates American College of Cardiology/American Heart Association; ASCVD, atherosclerotic cardiovascular disease; ATP III, Adult Treatment Panel III; LDL‐C, low‐density lipoprotein cholesterol.
Figure 2
Figure 2
Comparison of the proportion of nonprogressor and progressor in statin‐eligible population according to each set of guideline. Proportions were calculated within the total population (N=1289). ACC/AHA indicates American College of Cardiology/American Heart Association; ATP III, Adult Treatment Panel III; Not Rec, not recommended for statin; Rec, Recommended for statin.

Comment in

References

    1. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd‐Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;129:S1–45. - PubMed
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–2497. - PubMed
    1. Kavousi M, Leening MJ, Nanchen D, Greenland P, Graham IM, Steyerberg EW, Ikram MA, Stricker BH, Hofman A, Franco OH. Comparison of application of the ACC/AHA guidelines, adult treatment panel III guidelines, and European society of cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311:1416–1423. - PubMed
    1. Muntner P, Colantonio LD, Cushman M, Goff DC Jr, Howard G, Howard VJ, Kissela B, Levitan EB, Lloyd‐Jones DM, Safford MM. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311:1406–1415. - PMC - PubMed
    1. Pursnani A, Mayrhofer T, Ferencik M, Hoffmann U. The 2013 ACC/AHA cardiovascular prevention guidelines improve alignment of statin therapy with coronary atherosclerosis as detected by coronary computed tomography angiography. Atherosclerosis. 2014;237:314–318. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources